Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line

Aktuelle Urologie

Volumn 34, Issue 4, 2003, Pages 250-252

  Nakagawa, Masayuki ^a   Enokida, H ^a   Gotanda, T ^a   Tachiwada, T ^a   Imazono, Y ^a   Kubo, H ^a   Nishiyama, K ^a   Suzuki, S ^b   Inomata, K ^b   Kishiye, T ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NISSHIN SEIFUN GROUP INC   (Japan)

Author keywords

Bladder cancer; Isoprenoid; P glycoprotein; Taxol resistance

Indexed keywords

BENZENE DERIVATIVE; BENZYL DERIVATIVE; CEPHARANTHINE; CYCLOHEXANE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GYRASE INHIBITOR; ISOPRENE; ISOPRENOID; MITOXANTRONE; N 5228; N,N' BIS(3,4 DIMETHOXYBENZYL) N SOLANESYL 1,2 DIAMINOCYCLOHEXANE; N,N' BIS(3,4 DIMETHOXYBENZYL) N SOLANESYLETHYLENEDIAMINE; PACLITAXEL; PAK 104 P; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BLADDER CANCER; CANCER CELL CULTURE; CELL ISOLATION; CONFERENCE PAPER; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TRANSPORT; HUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; P-GLYCOPROTEIN; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; URINARY BLADDER NEOPLASMS;

EID: 0041331540     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41608     Document Type: Conference Paper

References (10)

1. Bremnes RM, Sundstrom S, Vilsvik J, Aasebo U. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 2001; 19: 3532-3538
2. Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 2001; 58: 59-64
3. Vaishampayan U, Flaherty L, Du W, Hussain M. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 2001; 92: 519-523
4. Zhou J, Cheng SC, Luo D, Xie Y. Study of multi-drug resistant mechanism in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line. Biochem Biophys Res Commun 2001; 280: 1237-1242
5. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T et al. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 1994; 85: 290-297
6. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993; 15: 55-61
7. Dumontet C, Sikic BI. Mechanisms of action of and resistant to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17: 1061-1070
8. Nakagawa M, Akiyama S, Yamaguchi T, Shiraishi N, Ogata J, Kuwano M. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. Cancer Res 1986; 46: 4453-4457
9. Zhang L, Sachs CW, Fine RL, Casey PJ. Interaction of prenylcysteine methyl esters with the multidrug resistance transporter. J Biol Chem 1994; 269: 15973-15976
10. Wiese M, Pajeva IK. Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 2001; 8: 685-713